Safety of Percutaneous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued…

889 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). (2013, methodology): “1% of patients in the PROTECT AF trial, but with operator experience, there were no procedurerelated strokes in the CAP registry (11) or in the ASAP study.”
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. (2012, background): “AF (CAP) registry is following patient outcomes beyond the end of enrolment and demonstrates a “learning curve effect” with reduced complication rates after the end of the trial.(118) A second randomized trial, PREVAIL (Prospective Randomized EVAluation of the Watchman LAA closure device In patients”